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Human Somatic Mutation AssaysAs
Biomarkers of Carcinogenesis
by R J. E. Compton,* Kim Hooper,t and Martyn T.
Smith*
lhispaperdescribesfourassaysthatdetectsomaticgenemu inhumans:thehypanthine-guin phosphoribosyl
transferase assay, theglycophorinAassay, theHLA-Aassay, andthesicklecellhemoglobinassay. Somaticgenemuta-
tioncanbeconsideredabionarkerofcarciogenesi,andassaysforsomaticmutationm yassistepidemiologists instudies
thatattempttoidentify factorsassociated withincreased risksofcancer.Practcal aspectsoftheuseoftheseassaysare
discussed.
Introduction
Cancerdevelopmentis amultistep processthatmaytake years
inhumans. Critical stepsinthe process appeartobetheproduc-
tionofstablechangesinthegeneticmaterial, calledmutations,
and subsequent cell proliferation that produces daughter cells
with mutated DNA.
Anumberofmutational events arethoughttobe necessary to
convert anormalcellinto amalignantcancercell. Forexample,
sequentialmutationalchangeshavebeenidentifiedintissuesof
thecolon that arerelatedtoclinical stages intheprogressionof
colon cancer (1). Thedevelopmentofsomatic mutation assays
asbiomarkers ofthecarcinogenic process may, therefore, help
epidemiologists linkcarcinogenic exposures to canceroutcome
in humans by looking at events early on inthe cancer process.
This paperprovides anoverview ofcurrenthumansomatic gene




Thelinesofevidencethatlink somatic mutation with cancer
can bebroadly summarized as follows.
a) Cancersoften arise inproliferating tissues incontactwith
theenvironment, e.g., themouth, gut, skin, andlungs (2). In a
tissue inwhichthereisrapidcellproliferation, damagetoDNA
may notbecompletely repairedbeforecelldivision occurs. The
damage may then be passed on and made permanent in DNA
strands ofthedaughter cells.
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b) ManycarcinogensbindtoorcausemutationinDNA. For






d) Stable, nonrandom changes in the genetic material are
associated with certain cancers. For example, most cases of
chronicmyelogenousleukemiaexhibitacharacteristic "Phila-
delphia" chromosome, which is the product of a reciprocal
translocationbetweenchromosomes22 and9 (5).
e) A tumor probably arises from the clonal expansion ofa
single cell, based upon observations ofmonoclonal X-inacti-
vationpatterns intumors (6).
J) Certaingeneticconditions with ahigh riskofcancerhave
beenshowntohavedefectsinDNArepairprocesses, e.g.,ataxia





ofmutations withtheyears (11). Biomarkers ofmutation may,
therefore, beusefulasindicatorsofeffectsotherthancancer. It
shouldberemembered, however,thatmutationalsomayhaveno




chromosomal structure andassays ofchange atthelevel ofthe
gene. TheDNAinthenucleus ispackagedintochromosomes,
which are linear DNA molecules with secondary and tertiary
structure. GenesareshortpiecesofDNAthatcodeforRNAand
proteins, andageneisvery smallcomparedtoachromosome:
genesmakeupapproximately 3+% ofachromosome, andmany
genes resideoneachchromosome (13).COMP7TONETAL.
Assays of change in chromosome structure include the
chromosomeaberrationassay, whichscoresthenumberofab-
normal, broken, or missing chromosomes in metaphase cells
(14); the SCE assay, which counts sister chromatid exchanges
(exchanges of identical pieces of chromosomes in duplicated
sisterchromatidsduringcellreplication) inmetaphasecells(15);
and the micronucleus assay, which measures the fiequency of
micronucleus formation (chromosomes or fragments of
chromosomes lost to thecytoplasm during cell division) (16).
These assays are usually performed in whitebloodcells (lym-
phocytes). Suchassaysmayreflectdamageaswellasmutation,
since notalloftheevents scored reflectaheritablechangethat
is transmitted from a cell to a daughter cell, the definition of
mutation. Thisarticlefocusesonhumansomaticmutationassays
atthelevelofthegene.
There arepractical constraints to measuring genemutations




Only a small number ofhuman mutation assays have been




canbeused tomakedetectionofmutantsrelatively simple. All
ofthecurrenthumanmutationassaysusebloodcells, andalluse
achangeinorabsenceofanormallyfunctioningproteintodetect
mutations inthe gene coding fortheprotein.






be deactivated by mutation (17). Even in the cases where it is
possible to detect a change in these "cancer" genes, however,
there is currently no method for identifying the mutant cells
against the background ofnormal cells. Identifying cells with
mutations in cancer genes using presenttechnology would re-
quirescreeningthousandsormillionsofcoloniesgrownfromin-
dividual cells, and this is not practical. Current human gene
mutation assays instead screen formutationsthatcanbeeasily












tidebases(adenine, dymine,guanine, andcytosine, whichmake
upthegeneticcode)madedenovo, orfrombasesrecycledfrom





mal white blood cells incorporate the toxic analog into newly
synthesized DNA, leadingtocelldeath (Fig. La). Mutantcells
thathaveanonfunctioningHPRTenzymedonotincorporatethe
toxicanalogandsurvive(Fig. Ib). FortheHPRTmutationassay,








the gene were present, the loss ofone copy would be hard to
detect, as the other copy would probably supply the missing
function. Onlyonecopyofthehprtgeneispresentbecauseitis
located on the X chromosome, and there is only one active X
chromosomepercell. Humanshave22pairsofautosomal (i.e.,






Because only one chromosome carries the functional hprt
gene,theHPRTassayprobablydoesnotdetectmutationsrequir-
ing interaction between both chromosomes ofa pair. Recent
evidence from cancer biology indicates that chromosome-










chromosome 13) have been altered and have lostthe ability to
produce a protein that suppresses cancer. The rb gene is a
member ofthe class ofrecently discovered tumor-suppressor
genes. Thechildren withthehereditary (from aparent or ade
novogermlinemutation)formofretinoblastomahaveonecon-
stitutivedefectivecopyofthisgene, andtumorsapparentlyarise



























FIGURE 1. The HPRT mutation assay selects mutants from T-lymphocytes by exploiting abiochemical pathway ofDNA synthesis. DNA is made from new or
recycled nucleotidebases. HPRTisoneoftheenzymes inthesalvage, orrecycling, pathway. In nonmutantcellswith functional HPRTenzyme, atoxicanalog
ofnucleotidebases (6-thioguanine) isincorporated intoDNA,leadingtocelldeath. Inmutantcellsthatlackafunctional HPRTenzyme, thetoxicanalog is not
incorporated, and the cells survive.
basesequenceofDNA. Mutationsofthistypearedetectedbythe
HPRTassaysincetheyrequirethatonlyonecopyofthegenebe
present. "Gene-duplicating" mutations arethose inwhich the
inherited dysfunctional copy ofthe gene ontheotherchromo-




events obviously require that both chromosomes of a pair be
present.
Two recently developed human mutation assays, the gly-
cophorinAassay(GPA)andtheHLA-Aassays, areabletodetect
chromosome-chromosome interactions because the genes
studiedarelocatedonautosomal (nonsex)chromosomes. (This
means there are two copies of each gene, one on each ofthe
paired chromosomes.) Both methods assay for the loss of a
surface protein on cells heterozygous for the genemaking the
protein. Thecells mustbeheterozygous because amutation at




mutant cells are detectedby the loss oftheprotein, thesecells
would notbedetected asmutants.
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FiGuRA 2. Mutationalmechani generating lossoftumor-suppressorgenes
inretinoblastoma. Retinoblastomaapparentlyarisesduetolossofboth func-
tionalcopiesoftherbgeneonchromosome 13. AnalysisoftumorDNAin-
dicates that two general types ofmutational mechanisms, gene loss/inac-
tivatingandgeneduplicatng, leadtolossoftheremainingfuncionalrbgene
inchildren with aconstitutive defective rbgene.
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GPAAssay
TheGPA assay measures cells thathavelostoneformofthe
GPA protein present on the surfaceofredblood cells (23,24).
The gene has two alleles called M and N and is located on








can discriminate between the M and N forms ofglycoprotein.
Thebloodcellsarefirstfixed(surfaceproteinsarecross-linked)
tostabilizethecellsandpreventagglutinationwhenreactedwith
antibodies. The antibodies are labeled with fluorescent mole-




M on the cell surface will fail to bind antibody to M and will
fluoresce green only (Fig. 3). The antibody-bound cells are
analyzedbyaflowcytometer, whichmeasuresfluorescencefrom







thenormal amountofNonthecell surfaceand noM-binding,
andpresumablyarisefromgene-duplicatingmutations (Fig. 3).
Finding mutant cells by screening all cells (as opposed to the
HPRTassaywhereallnormalcellsareeliminated)ismadepossi-
blebecauseflowcytometers cananalyzecellsveryrapidly. Inthe
GPAassay, fluorescence fromeachoffivemillioncells canbe
measuredin20minandthemutantcells enumerated.
The GPA assay has theadvantage that it can detectchromo-
some-chromosomeinteractions suchasmitoticrecombination.
It is limited in thatthe redblood cell lacks a nucleus, and this





The recently developed HLA-A assay (25) is performed on
whitebloodcells, whichcontainDNA, andthereforetheassay
can be used to provide detailed information on mutational
mechanism. HLA-Aisasurfaceproteinfoundonmostnucleated
cellsinthebodyandisinvolvedintheimmuneresponseandself
versus nonself discrimination (26). The HLA-A gene is on
0 MfonmdPA > RED aand-MAbFM
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FIGURE 3. TheGPA assay requiresblood samples from personsheterozygous forglycophorinA, acell surfiaceprotein onredbloodcells. In a normal redblood
precursortell fromaGPAheterozygote, onechromosomeofthechromosome4paircarries the MformofGPAand onetheNform(left). Mutantcells mayarise
fromgene-loss/inactivating mutations(calledNO)andgene-duplicating mutations(calledNN)(left). Therightportionofthefigureshows anormalheterozygous
redbloodcellwithbothMandNbloodgroupproteinsonthecellsurface, andmutantcellswithnormal(NO)ortwicenormal (NN)amountsofNGPA,butwhich
lacknormal MGPA. Normalandmutantcells arereactedwithanti-GPAMandanti-GPANantibodieslabeledwithfluorescentmolecules, anti-Mwithredand





protein, i.e., have more thanone formontheircells.
The HLA-A human somatic mutation assay is similar to the
GPAassay inthatmutantsaredetectedby lackofantibodybin-
dingtoacellsurfaceprotein. Inordertodetectmutants,however,
normal cells are eliminated as in the HPRT assay, rather than
counted as inthe GPA assay.
To determine HLA-A mutant frequencies for an individual,
whitebloodcellsareisolatedfromabloodsampleandtypedwith
HLA-A antibodies. The assay currently works on individuals
heterozygous forA2orA3 forms (alleles)ofHLA-A. Morethan
60% ofanaveragepopulationisheterozygousforoneortheother
ofthese alleles. Blood from an A2Ax or A3Ax blood type in-




dition of complement, therefore, kills the normal A2 or A3
antibody-covered cells, andmutantcellswithalteredormissing
HLA-Aproteinfailtobindtheantibodyandsurvive(Fig. 4). The





ble for anaverage ofone-third ofthemutations observed (27).
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FIGURE 4. The HLA-A assay requires blood samples from subjects hetero-
zygousattheHLA-Agene,agenewithmanyalleles. Inthecurrentassay, sub-
jectsmustbeheterozygousforA2orA3, i.e., A2AxorA3Ax, whereAx =
otherHLA-Aallele. Theassay measures mutantT-lymphocytes that lack a
normal A2 or A3 protein due to mutation at the HLA-A gene. To identify
mutants, T-lymphocytes arereacted withanti-HLA-A-A2 or -A3 antibody.
Normalcellsbindantibodyandarekilledbytheadditionofcomplement(C'),
whichtargetsantibody-bound cells. Mutantcellsdo notbindantibody and
survive. The assay detects gene-loss/inactivating mutants and gene-dupli-
cating mutants, shownatthe lowerleft.
Hb-S andOtherAssays
Afourthhumansomaticmutationassay, Hb-S, detectsthepro-
duction of a mutant form of hemoglobin (Hb-S) caused by a
specificpointmutationinoneoftheHbgenes (28-30). Hb-Sis
thehemoglobinresponsibleforsicklecellanemia. Fluorescently
labeled antibodies for the mutated Hb are added to blood
preparations fixed on a slide. The slide is then scanned by
microscopy (automatedimageanalysis)todetectanti-Hb-San-
tibodybinding (28). Thisassaydetectsonlyonespecific muta-
tion, achangeofthebaseadeninetothymine. Theassaytherefore
does notdetectawide rangeofmutational mechanisms and so
hasamuchlowermutantfrequencythanisobservedineitherthe
HPRT, GPA, orHLA-Aassays. However, modifications arebe-
ing introduced that will increase the number of mutations
detected (28).






intissues thought tobedirectly targetedby acertainexposure.
Currentsomatic mutationassaysareallperformedononetissue,
theblood, andthereareuncertainties inherent inextrapolating
from mutations in a nontarget tissue to mutations in a target





Practical Considerations in Using
These Assays in Epidemiological
Studies




















ment to be detected. The HLA-A and HPRT assays record


















on smokers versus nonsmokers, and on persons with cancer-
pronesyndromes(17-19,33-56).TheGPAassayhasbeenapplied
to radiation and chemotherapy-exposed individuals, persons
with occupational exposures to styrene, persons with cancer-
prone syndromes, and a limited general population
(23,24,32,57-63). The HLA-A assay has been applied to the
study of the effects of age and to chemotherapy-exposed in-
dividuals (25,27,64,65). The Hb-S assay hasbeenappliedto a
small number ofsubjects with different mutagenic exposures
(28) and withcancer-prone syndromes.
Further studies arerequired to supply epidemiologists with




tors intheHPRT assay. b) The rangeofvalues fortheseassays
among individuals in the general population (interindividual
variability) needs to becharacterized, as does thevariation in
assay values for given individuals over time (intra-individual
variation). Someofthis information is available forthe HPRT
assay (40). Subpopulations with extremely high or low assay








If further information can be collected, current and future
assaysofsomaticmutationinhumansshowpromiseforarange
ofepidemiological studies: investigatingcancerclusters; iden-
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